J&J Gets FDA Nod for Plaque Psoriasis Pill Positioned to Compete With Injectables

FDA approval of Icotyde covers the treatment of adults and adolescents with moderate-to-severe plaque psoriasis. This once-daily pill, developed by partners Johnson & Johnson and Protagonist Therapeutics, offers an easier dosing option compared to injectables and is projected to become a blockbuster seller across several immunological indications. The post J&J Gets FDA Nod for Plaque…

Read More

Would delinking PBM reimbursement from rebates save money?

According to a Health Affairs Scholar paper by Geoffrey Joyce out this month, the answer is ‘yes’. He writes: Most PBM contracts tie their compensation to a percentage of a drug’s list price, creating a financial incentive to favor high-cost, high-rebate drugs on plan formularies at the expense of lower-cost generics and biosimilars. Furthermore, the…

Read More

Health care spending makes up 18% of the US Economy

That is according to the 2024 national health expenditure data published in Health Affairs last week (Hartman et al. 2026). Here is the abstract: Health care spending in the US reached $5.3 trillion and increased 7.2 percent in 2024, similar to growth of 7.4 percent in 2023, as increased demand for health care influenced this two-year trend. As…

Read More